| WB | 1/1000 | Human,Mouse,Rat |
| IF | 咨询技术 | Human,Mouse,Rat |
| IHC | 咨询技术 | Human,Mouse,Rat |
| ICC | 技术咨询 | Human,Mouse,Rat |
| FCM | 咨询技术 | Human,Mouse,Rat |
| Elisa | 咨询技术 | Human,Mouse,Rat |
| Aliases | Calcium release-activated calcium channel protein 1, Protein orai-1, Transmembrane protein 142A, ORAI1, CRACM1, TMEM142A |
| Entrez GeneID | 84876 |
| WB Predicted band size | 32.7kDa |
| Host/Isotype | Rabbit IgG |
| Antibody Type | Primary antibody |
| Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| Species Reactivity | Human |
| Immunogen | This ORAI1 antibody is generated from rabbits immunized with a KLH conjugated synthetic peptide between 269-298 amino acids from the C-terminal region of human ORAI1. |
| Formulation | Purified antibody in PBS with 0.05% sodium azide. |
+ +
以下是关于ORAI1抗体的3篇参考文献及其摘要内容：
---
1. **文献名称**: *CRAC channels and disease — From human CRAC channelopathies and animal models to novel drugs*
**作者**: Feske, S., et al.
**摘要**: 该综述总结了ORAI1作为钙释放激活钙通道(CRAC)的核心组分在免疫系统中的关键作用，并讨论了ORAI1抗体在检测其表达及功能研究中的应用。研究强调了ORAI1基因突变导致的人类免疫缺陷疾病(如严重联合免疫缺陷，SCID)，并利用抗体实验验证了ORAI1蛋白在患者淋巴细胞中的异常表达。
---
2. **文献名称**: *Crystal structure of the calcium release-activated calcium channel Orai*
**作者**: Hou, X., et al.
**摘要**: 本研究通过X射线晶体学解析了ORAI1通道的三维结构，揭示了其钙离子选择性渗透的分子机制。研究中利用特异性ORAI1抗体纯化蛋白并验证其表达，为理解CRAC通道的功能及靶向药物设计提供了结构基础。
---
3. **文献名称**: *Targeting ORAI1-mediated store-operated calcium entry in cancer*
**作者**: Stauderman, K.A., et al.
**摘要**: 文章探讨了ORAI1在肿瘤细胞增殖和迁移中的作用，通过使用ORAI1抗体阻断其功能或敲低蛋白表达，证实了抑制CRAC通道可减少癌细胞钙信号传导并抑制肿瘤生长，提示ORAI1作为癌症治疗靶点的潜力。
---
以上文献均涉及ORAI1抗体的实验应用(如蛋白检测、功能抑制)，并聚焦于其在免疫学、结构生物学及肿瘤学中的机制研究。
ORAI1 antibodies are essential tools for studying the ORAI1 protein, a critical component of calcium release-activated calcium (CRAC) channels. These channels mediate store-operated calcium entry (SOCE), a key signaling mechanism regulating immune cell activation, gene transcription, and cellular processes like proliferation and apoptosis. ORAI1. located on the plasma membrane, interacts with stromal interaction molecule 1 (STIM1) in the endoplasmic reticulum. Upon calcium store depletion, STIM1 oligomerizes and activates ORAI1. forming functional CRAC channels to replenish intracellular calcium.
Antibodies targeting ORAI1 are widely used in research to investigate its expression, localization, and interaction partners. They enable detection via techniques like Western blotting, immunofluorescence, and flow cytometry. ORAI1 dysfunction is linked to severe immunodeficiency (e.g., CRAC channelopathy), autoimmune disorders, and cancers, making these antibodies vital for mechanistic studies. Additionally, they aid in evaluating ORAI1's role in T-cell activation, mast cell responses, and cancer metastasis. Commercial ORAI1 antibodies are typically raised against specific epitopes (e.g., N-terminal or C-terminal regions) and validated for species reactivity (human, mouse, rat). Proper validation ensures specificity, as off-target binding to homologous proteins (ORAI2/3) can occur. Research using these antibodies has advanced therapeutic targeting of CRAC channels in immune-related diseases.
×
